Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-11-10
1999-02-02
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514299, 514340, 514342, 514365, 514366, 514367, 514370, A61K 31425
Patent
active
058665951
ABSTRACT:
According to the present invention, compounds selected from the thiozole class of organic molecules are employed as antagonists for receptor-operated ion channels (ROICs) useful in the treatment of a variety of disease states in which ROICs are implicated. ROICs of particular interest are receptor-operated calcium channels (ROCCs). Compounds of particular interest with respect to the subject invention are compounds of the thiazolidinedione class of organic molecules, more particularly ciglitazone. Disease states in which particular utility is expected include vasculoproliferative diseases such as atherosclerosis, restenosis following angioplasty, and other conditions in which PDGF is known to play a role. The utility of the present invention with respect to further studies on the operation of ROICs and ROCCs and their role in disease will be apparent to those of skill in the art.
REFERENCES:
patent: 4175130 (1979-11-01), Yamanaka et al.
patent: 4346088 (1982-08-01), Lang et al.
patent: 4728739 (1988-03-01), Kees et al.
patent: 4791125 (1988-12-01), Clark
patent: 4798835 (1989-01-01), Krupp et al.
patent: 5053420 (1991-10-01), Pershadsingh
patent: 5095027 (1992-03-01), Goldberg et al.
patent: 5252735 (1993-10-01), Morris
Chemical Abstracts An 108: 129343. Haragun et al. "Pradipocyte differentiation in vitro: identification of a highly active adipogenic agent," J. Cell. Physiol. , (1988), 134 (1), 124-30.
Meuck Manual pp. 386-387, 1038-1039, 1982.
Pershadsingh & McDonald, "Hormone-receptor coupling and the molecular mechanism of insulin action in the adippococyte: a Paradigim for Ca .sup.2 homeostasis in the initiation of the insulin-induced metabolic cascade"Cell Calcium 5: 111-130, 1994
Colca et al. "Ciglitazone . . . " Metabolism vol 37 (3): 276-280 (1980).
Kurtz Theodore W.
Pershadsingh Harrihar A.
MacMillan Keith D.
The Regents of the University of California
LandOfFree
Calcium antagonists for treatment of vascular restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium antagonists for treatment of vascular restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium antagonists for treatment of vascular restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117843